Universe Pharmaceuticals (UPC) director Yu Yongping files initial Form 3

Rhea-AI Filing Summary

Universe Pharmaceuticals INC director Yu Yongping has filed an initial insider ownership report on Form 3 for the company’s common equity. The filing lists no insider transactions or option exercises and shows no derivative positions, serving mainly as a baseline disclosure of Yu Yongping’s status as a director.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Yu Yongping

(Last) (First) (Middle)

265 JINGJIU AVENUE

JINGGANGSHAN ECON. AND TECH. DEV. ZONE

(Street)

JI'AN, JIANGXI 343100

(City) (State) (Zip)

CHINA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Universe Pharmaceuticals INC [ UPC ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Yongping Yu	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Yu Yongping’s Form 3 filing mean for UPC investors?

The Form 3 shows that director Yu Yongping has formally reported insider status at Universe Pharmaceuticals INC (UPC). It lists no transactions or derivative positions, acting mainly as a baseline regulatory disclosure of insider status.

Does the UPC Form 3 for Yu Yongping report any share purchases or sales?

No, the Form 3 for Yu Yongping reports no purchases or sales. The transaction summary shows zero buy, sell, exercise, gift, tax-withholding, or restructuring entries, indicating no trading activity in this filing.

Is Yu Yongping a director or officer of Universe Pharmaceuticals INC (UPC)?

The filing identifies Yu Yongping as a director of Universe Pharmaceuticals INC. It does not list any officer role or title, and confirms there is no ten percent owner status associated with this reporting person.

Does the UPC Form 3 show any derivative securities for Yu Yongping?

No, the Form 3 indicates no derivative securities for Yu Yongping. The derivative summary is empty and the transaction summary shows zero derivative transactions, suggesting no options or similar instruments are reported in this filing.

Are there any notable footnotes in Yu Yongping’s Form 3 for UPC?

The Form 3 includes a footnotes section, but it contains no substantive entries beyond a null value. There are no additional explanations about voting power, investment authority, or related entities in the provided data.